peptides for FAQ

DIHEXA's 5–7 day effect window allows dosing every other day or even twice weekly without losing efficacy. Published University of Arizona data confirm sustained cognitive benefit with 3× weekly dosing. Alternatively, switch from daily Semax subcutaneous injections to intranasal formulation, which reduces peptide waste (lower dose required for equivalent CNS exposure) and eliminates injection supplies. The Cognitive Function peptide stack combines multiple mechanisms in one formulation, reducing per-animal costs while maintaining BDNF elevation.

Sequence administration based on injury phase rather than administering all three simultaneously. Start with BPC-157 during the acute inflammatory phase (days 0–7), introduce TB-500 during proliferation (days 7–21), and continue GHK-Cu throughout the entire timeline including final remodeling (days 0–90). Simultaneous administration of all three peptides during acute inflammation can produce overlapping inflammatory modulation effects that obscure individual contributions to measured outcomes. Phase-sequential stacking allows clearer attribution of healing effects to specific peptides while still leveraging complementary mechanisms across the complete healing timeline.

Use Semax or Selank delivered intranasally. Both achieve direct brain access through olfactory epithelium transport, documented in pharmacokinetic studies showing peak CNS concentrations within 20–40 minutes. Cerebrolysin requires IV or IM administration, making it impractical for protocols without medical supervision or institutional oversight.

Combining BPC-157 with TB-500 is common in orthopedic research because their mechanisms are complementary. BPC-157 restores blood flow while TB-500 drives cell migration. Co-administration doesn't cause interference because they target different molecular pathways. However, combining GHK-Cu with other copper-binding compounds (like EDTA in some bacteriostatic water formulations) can chelate copper away from the peptide, rendering it inactive. Use copper-free diluents when working with GHK-Cu, and avoid mixing peptides in the same syringe unless stability data confirms compatibility.

Discard it. Don't attempt to salvage it by re-freezing. Peptide tertiary structure denatures irreversibly once exposed to temperatures above 8°C for extended periods, and there's no visual or functional test you can run in-house to confirm potency. A clear solution looks identical whether the peptide is bioactive or degraded. If your shipment arrives with a melted cold pack or the temperature logger shows excursions above −10°C, contact the supplier for replacement before starting any experiments.

Resume at your previous dose without doubling up. Semax and Selank work through gene expression changes that accumulate over days, not hours. Missing 2–3 days won't erase prior gains, but it will delay further progress. The half-life of circulating peptide is short (minutes), but the downstream effects on BDNF expression and enkephalin metabolism persist longer. If you miss more than 5 consecutive days, consider restarting the protocol from day one to re-establish consistent neurotrophin signaling.

Plan multiple reconstitution cycles rather than extending a single vial beyond its stability window. Reconstituted peptides in bacteriostatic water maintain potency for 28 days at 2–8°C, after which degradation accelerates regardless of visual appearance. For a 12-week study, reconstitute fresh vials at weeks 0, 4, and 8. Using expired peptide in weeks 9–12 introduces dose variability that confounds your results. Label each vial with reconstitution date and discard at 28 days even if solution remains. This protocol adds minor cost but eliminates the single largest source of within-study variance in longitudinal peptide research.

Freeze reconstituted peptides at −20°C in single-use aliquots with 10% DMSO or glycerol as a cryoprotectant. Standard reconstitution in bacteriostatic water maintains stability for 28 days at 2–8°C, but longer storage requires freezing to prevent oxidation and bacterial growth. Avoid repeated freeze-thaw cycles. Each cycle degrades approximately 5–8% of peptide content through ice crystal shearing and oxidative stress. Aliquot the reconstituted solution into volumes needed for single experiments, freeze once, and thaw only when ready to use.

Consider peptide intervention targeting mucosal repair and immune function. Not just bacterial load. Recurrent SIBO after multiple antibiotic rounds suggests the gut lining can't maintain microbial balance even after bacterial eradication. BPC-157 or thymosin alpha-1 protocols focus on restoring the epithelial and immune integrity that prevent recolonisation. Research shows peptides that enhance tight junction protein expression reduce relapse rates when combined with prokinetic agents to restore motility.

Pretreat with a GnRH antagonist (cetrorelix 0.25 mg/day SC) for 48 hours to suppress endogenous LH pulsatility, then administer exogenous recombinant FSH or FSH-beta fragments at your target dose. The antagonist blocks pituitary LH release without affecting peripheral FSH receptor signaling. This is the standard approach in IVF research when isolating follicular development from androgen synthesis. Monitor LH levels at 24-hour intervals; if suppression isn't complete (LH >1 IU/L), increase antagonist dose to 0.5 mg/day.

Kisspeptin restores GnRH pulsatility acutely but does not fix the metabolic suppression causing hypothalamic amenorrhea. If exogenous kisspeptin produces an LH surge but menstruation does not resume, the issue is downstream. Either insufficient endometrial development from prolonged low estradiol or incomplete ovarian response due to suppressed follicular reserve. Kisspeptin is a diagnostic tool that confirms HPG axis capacity; it does not replace weight restoration, adequate caloric intake, and reduced exercise volume.

BPC-157's mechanism applies to esophageal epithelium as effectively as gastric mucosa. The VEGFR2 and FAK-paxillin pathways function identically across gastrointestinal epithelial tissues. Studies in World Journal of Gastroenterology demonstrate that BPC-157 accelerates healing of experimental esophageal lesions with similar efficacy to gastric ulcer models. The primary consideration is administration route: systemic injection allows peptide distribution to esophageal tissue, while topical application (in solution form) may concentrate peptide exposure at the injury site.

Most TB-500 discrepancies trace to light exposure during storage or administration. The peptide's methionine residues oxidize rapidly under standard lab lighting. Forming methionine sulfoxide, which has zero actin-binding activity. If your reconstituted TB-500 was stored in clear vials or drawn under bright overhead lights, you administered degraded peptide. Switch to amber vials, prepare doses under reduced lighting, and refrigerate immediately. Potency loss from oxidation isn't recoverable. Start with fresh peptide stock.

Discard them immediately if they were supposed to arrive frozen. Lyophilized peptides shipped at ambient temperature (above 8°C) for more than 48 hours have undergone oxidation that destroys methionine residues and cleaves disulfide bonds. Both structural elements required for receptor binding. The peptide may reconstitute normally and appear identical, but its three-dimensional structure has collapsed. No visual inspection, dissolution test, or home assay can detect this degradation. You're injecting an inactive compound.

Two possibilities: peptide quality is poor (no HPLC verification from your supplier), or you're not applying sufficient mechanical load during recovery. Peptides modulate biochemical pathways, but collagen organisation requires progressive tensile stress. Eccentric loading exercises that gradually increase resistance are non-negotiable. If you've verified peptide source quality and you're following structured PT protocols, consider adding TB-500 for angiogenic support or extending the protocol to six weeks. Some ligament injuries. Particularly those involving fibrocartilage transitions like the ACL femoral attachment. Take longer to remodel regardless of peptide use.

Use subcutaneous osmotic pumps. Alzet model 1004 pumps deliver 0.11 μL/hour for 28 days, sufficient for sustained Selank or MOTS-c exposure at therapeutic concentrations. Load the pump with 100 μL peptide solution at 10× final desired concentration (e.g., 500 μg/mL Selank for 50 μg/kg/day delivery to a 25 g mouse). Pumps eliminate injection stress artefacts in behavioural assays but require surgical implantation under isoflurane anaesthesia. Factor in 7-day recovery before experimental endpoints.

Use Selank intranasally at research doses of 300–600mcg per administration. The GABAergic modulation produces anxiolytic effects within 20–30 minutes without the cognitive impairment or motor sedation associated with benzodiazepines. Research protocols show efficacy for 4–6 hours per dose. Twice-daily administration maintains effect without tolerance buildup.

It's likely degraded significantly. Peptides are thermolabile and oxidatively unstable. Exposure to typical bathroom temperatures (28–32°C) and humidity degrades acetyl hexapeptide-8 by approximately 40% within 60 days based on accelerated stability testing. If the product wasn't stored in the refrigerator in airless packaging, assume reduced potency. Oxidized peptides aren't harmful, but they're biologically inactive. For future purchases, choose products in opaque airless pumps and store them refrigerated between uses.

Verify there are no contraindications between peptide protocols and existing pharmacotherapy. Particularly with SSRIs, benzodiazepines, or dopamine agonists. Selank enhances serotonergic signaling, which could theoretically potentiate SSRI effects; MK-677 increases cortisol alongside GH, which may be contraindicated in uncontrolled diabetes or Cushing's syndrome. DSIP and Epithalon have minimal drug interaction risk because they work through endogenous neuropeptide pathways rather than neurotransmitter receptor modulation. BPC-157 has been studied alongside NSAIDs, corticosteroids, and immunosuppressants without adverse interactions. Always disclose peptide use to your prescribing physician if you're on chronic medication. Peptide synergy with existing treatments can enhance efficacy but may also require dose adjustment.

Discard it. A single temperature excursion above 8°C for more than 2 hours causes protein denaturation. The peptide's three-dimensional structure collapses, rendering it biologically inactive. You can't visually detect this degradation, and potency testing at home is impossible. Using degraded peptides wastes money and delays recovery because you're injecting an inactive compound while believing you're following a therapeutic protocol. Our team has seen this error more than any other in research settings. Proper refrigeration with backup power or a dedicated peptide cooler is non-negotiable.